Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.51 |
| ▸ | TPMT | P51580 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18582749 | 0.84 | EGFR (0.51) | ALDH1A1 | |
| SCHEMBL18582921 | 0.83 | ALDH1A1 (0.47) | TTRESR2L3MBTL1ALDH1A1CES2 | |
| SCHEMBL8334930 | 0.82 | TTR (0.54) | TTRTPMTKMODHODHPTGER4 | |
| SCHEMBL21942025 | 0.79 | TTR (0.51) | TTRKMODHODHPTGER4ESR2 | |
| SCHEMBL21942026 | 0.79 | TTR (0.51) | TTRKMODHODHPTGER4ESR2 | |
| SCHEMBL18582698 | 0.79 | TTR (0.51) | TTRTPMTKMODHODHALDH1A1 | |
| SCHEMBL16384671 | 0.79 | TPMT (0.58) | TTRTPMTALDH1A1 | |
| SCHEMBL6735793 | 0.77 | TTR (0.49) | TTRTPMTL3MBTL1ALDH1A1 | |
| SCHEMBL29707122 | 0.77 | ESR2 (0.58) | TTRKMOESR2L3MBTL1ALDH1A1 | |
| SCHEMBL2744081 | 0.77 | GRIK1 (0.56) | TTRKMOL3MBTL1ALDH1A1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344617-A1 | PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS. | Ivachtchenko, Alexandre Vasilievich (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9790207-B2 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170066746-A1 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017039791-A1 | PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS. | ALLA CHEM, LLC (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066746-A1 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | POLR2A, GTF3C1, SSU72 | TTR 1075/4885TPMT 1012/4885KMO 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.